1 research outputs found
Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
Plasma phospholipid transfer protein (PLTP) transfers phospholipids
between lipoprotein particles and alters high density lipoprotein (HDL)
subfraction patterns in vitro, but its physiological function is poorly
understood. Transgenic mice that overexpress human PLTP were generated.
Compared with wild-type mice, these mice show a 2.5- to 4.5-fold increase
in PLTP activity in plasma. This results in a 30% to 40% decrease of
plasma levels of HDL cholesterol. Incubation of plasma from transgenic
animals at 37 degrees C reveals a 2- to 3-fold increase in the formation
of pre-beta-HDL compared with plasma from wild-type mice. Although
pre-beta-HDL is normally a minor subfraction of HDL, it is known to be a
very efficient acceptor of peripheral cell cholesterol and a key mediator
in reverse cholesterol transport. Further experiments show that plasma
from transgenic animals is much more efficient in preventing the
accumulation of intracellular cholesterol in macrophages than plasma from
wild-type mice, despite lower total HDL concentrations. It is concluded
that PLTP can act as an antiatherogenic factor preventing cellular
cholesterol overload by generation of pre-beta-HDL